| Schedule of prepaid expenses |
| |
|
March 31, |
|
|
December 31 |
|
| |
|
2023 |
|
|
2022 |
|
| Insurance |
|
$ |
754,217 |
|
|
$ |
1,027,292 |
|
| Research and development expense tax credit receivable |
|
|
322,129 |
|
|
|
546,563 |
|
| Professional fees |
|
|
438,501 |
|
|
|
310,017 |
|
| Value-added tax receivable |
|
|
9,734 |
|
|
|
48,774 |
|
| Taxes |
|
|
25,634 |
|
|
|
25,634 |
|
| |
|
$ |
1,550,215 |
|
|
$ |
1,958,280 |
|
|
| |
|
December 31, |
|
| |
|
2022 |
|
|
2021 |
|
| Insurance (1) |
|
$ |
1,027,292 |
|
|
$ |
1,937,693 |
|
| Research and development expense tax credit receivable |
|
|
546,563 |
|
|
|
644,513 |
|
| Professional fees (1) |
|
|
310,017 |
|
|
|
294,577 |
|
| Value-added tax receivable |
|
|
48,774 |
|
|
|
24,411 |
|
| Taxes |
|
|
25,634 |
|
|
|
25,634 |
|
| Other |
|
|
- |
|
|
|
49,755 |
|
| |
|
$ |
1,958,280 |
|
|
$ |
2,976,583 |
|
| (1) |
In the previously filed Annual Report on Form 10-K for the year ended December 31, 2021, the Insurance line item above included $213,974 of expenses related to Oxford agreements for our CBR Pharma subsidiary. In the current year, those same expenses are grouped into the Professional fees grouping. As such, for comparative purposes, that amount has been moved from the Insurance grouping to the Professional fees grouping for the 2021 period. |
|